Menu

OUR COMPANY

The Boehringer Ingelheim group is one of the world’s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, Boehringer Ingelheim operates globally with 146 affiliates and a total of more than 47,700 employees. The focus of the family-owned company, founded in 1885, is researching, developing, manufacturing and marketing new medications of high therapeutic value for human and veterinary medicines.

In the human pharmaceuticals business, Boehringer Ingelheim has medicines in its portfolio for the treatment of diseases of the respiratory tract, the cardiovascular system, the central nervous system, in addition to metabolic disorders, infectious diseases and cancer.

Average number of
employees by region
2014 2013 Change
Americas 14,033 15,038 –6.7 %
Europe 23,771 22,905 +3.8 %
Asia, Australia, Africa (AAA) 9,939 9,549 +4.1 %
47,743 47,492 +0.5 %

FINANCIAL HIGHLIGHTS

Amounts in EUR million, unless otherwise indicated 2014 2013 Change
Net sales 13,317 14,065 –5 %
Research and development 2,654 2,743 –3 %
Personnel costs 4,116 4,071 +1 %
Average number of employees 47,743 47,492 +1 %
Operating income 2,140 2,114 +1 %
– as % of net sales 16.1 % 15.0 %
Income after taxes 1,047 1,324 –21 %
– as % of net sales 7.9 % 9.4 %
Shareholders’ equity 8,111 7,122 +14 %
Return on shareholders’ equity 14.7 % 21.4 %
Cash flow 1,850 2,129 –13 %
Investments in tangible assets 548 558 –2 %
Depreciation of tangible assets 449 640 –30 %
Net sales by region
(IN EUR MILLION)
2014 2013 Change
Americas 5,937 6,411 –7.4 %
Europe 4,081 4,267 –4.4 %
Asia, Australia, Africa (AAA) 3,299 3,387 –2.6 %
Net sales by businesses
(IN EUR MILLION)
2014 2013 Change
Prescription Medicines 10,101 10,891 –7.3 %
Consumer Health Care 1,437 1,473 –2.5 %
Animal Health 1,130 1,070 +5.6 %
Biopharmaceuticals 501 449 +11.5 %
Industrial Customers and Other Sales 148 182 –18.6 %

PRESCRIPTION
MEDICINES

EUR10.1bn (–7.3 %)

Top 4 products

Net sales
(IN EUR MILLION)
2014 Change
SPIRIVA® 3,237 –8.9 %
PRADAXA® 1,198 –0.7 %
MICARDIS® 1,088 –20.8 %
COMBIVENT® 563 –20.7 %

CONSUMER HEALTH CARE

EUR1.4bn (–2.5 %)

Top 4 products

Net sales
(IN EUR MILLION)
2014 Change
BUSCOPAN® 222 +8.3 %
DULCOLAX® 200 +4.7 %
MUCOSOLVAN® 162 –12.0 %
PHARMATON® 136 –2.2 %

ANIMAL HEALTH

EUR1.1bn (+5.6 %)

Top 4 products

Net sales
(IN EUR MILLION)
2014 Change
INGELVAC CIRCOFLEX® 260 +0.2 %
METACAM® 93 +3.9 %
INGELVAC® PRRS 74 –6.9 %
DURAMUNE® 69 +32.3 %

worldwide

Americas


EUR 5,937m
(–7.4 %)

The Americas region remained the company’s most important sales market with a 44 % share of total sales. The USA is the most important market with sales of EUR 4,638 million.

Europe


EUR 4,081m
(–4.4 %)

The Europe region accounted for 31 % of total sales. Germany is the most important market with sales of EUR 912 million.

Asia,
Australia,
Africa (AAA)

EUR 3,299m
(–2.6 %)

The AAA region’s share of total sales was 25 %. Japan is the most important market with sales of EUR 1,736 million.

RESEARCH AND DEVELOPMENT

Boehringer Ingelheim’s focus is on the research and development of innovative medicines and therapies. Innovation is thus decisive for the future of the company.

Boehringer Ingelheim operates major R&D centres in, among other places, Germany (Biberach), the USA (Ridgefield) and Austria (Vienna).

The company relies not only on its own R&D, but also on an international network of cooperation partners from the academic, charitable and industrial fields.

Research and development 2014 2013
Expenditure in EUR million 2,654 2,743
– as % of net sales 19.9 19.5
Prescription Medicines expenditure in EUR million 2,333 2,444
– as % of Prescription Medicines net sales 23.1 22.4
Average number of employees 8,104 7,741
Investments in tangible assets in EUR million
(without investments in infrastructure)
78 114
Back to Top